ZURA BIO LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.41 USD | +21.82% |
|
+33.23% | -5.57% |
| Apr. 25 | Zura Bio Insider Bought Shares Worth $499,999, According to a Recent SEC Filing | MT |
| Apr. 25 | Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 289M |
|---|---|---|---|---|---|
| Net income 2024 * | -50M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.49
x | P/E ratio 2025 * |
-4.13
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +21.82% | ||
| 1 week | +33.23% | ||
| Current month | +71.60% | ||
| 1 month | +71.60% | ||
| 3 months | +32.43% | ||
| 6 months | -10.91% | ||
| Current year | -5.57% |
1 week
3.13
4.85
1 month
2.424.85
Current year
2.004.85
1 year
2.0014.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 22-01-17 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | Jan. 07 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 23-02-28 |
Steven Schoch
BRD | Director/Board Member | 64 | 23-02-28 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 4.64 | +5.22% | 283,293 |
| 24-04-26 | 4.41 | +21.82% | 897,979 |
| 24-04-25 | 3.62 | +9.37% | 338,797 |
| 24-04-24 | 3.31 | -4.89% | 849,725 |
| 24-04-23 | 3.48 | +5.14% | 133,183 |
End-of-day quote Nasdaq, April 25, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.64
USD
Average target price
16.4
USD
Spread / Average Target
+253.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.57% | 289M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +2.65% | 22.18B | |
| -16.67% | 21.2B | |
| -8.96% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- ZURA Stock
